Lloyd Miller

Company: Janssen Pharmaceuticals

Job title: Vice President, Immunodermatology Disease Area Leader

Seminars:

Development of a Novel Oral Peptide Therapy to Target the IL-23 Receptor in IL-23-Mediated Diseases 1:30 pm

Combining high potency with gastrointestinal stability provides an approach to overcome typically low systemic bioavailability of peptide therapeutics administered orally Targeting the IL-23 pathway with an oral peptide that binds the IL-23 receptor has the potential to be a first-in-class therapy for psoriasis and other IL-23-mediated diseasesRead more

day: Day One Translational Track PM